



Dr Tomas Salmonson
European Medicines Agency (EMA)
30 Churchill Place
Canary Wharf
London E14 5EU
E14 4HB United Kingdom



Munich, 23 March 2015

Withdrawal of Corluxin - EMEA/H/C/002830

Dear Dr Salmonson,

On behalf of the applicant FGK Representative Services GmbH, Granzer Regulatory Consulting & Services would like to inform you that, at this point of time, FGK Representative Services GmbH has taken the decision to withdraw the application for Marketing Authorisation of Corluxin® (mifepristone), which was intended to be used for the treatment of adult patients with endogenous Cushing's syndrome for whom surgery is not an option or for whom surgery has failed.

This withdrawal is based on the following reasons:

- Other: Strategic business reasons

There are no ongoing clinical trials or compassionate use programmes. Accordingly there are no consequences of the withdrawal.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMEA website.

Yours sincerely,

Granzer Regulatory Consulting & Services

